GlaxoSmithKline Financial Statements (GSK)
|
|
|
|
Report date
|
|
|
31.12.2021 |
31.12.2022 |
05.03.2024 |
03.03.2025 |
06.03.2026 |
|
29.04.2026 |
|
Currency
|
|
|
GBP |
GBP |
GBP |
GBP |
GBP |
|
GBP |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, £ |
? |
|
24 696 000 000 |
29 324 000 000 |
30 328 000 000 |
31 376 000 000 |
32 667 000 000 |
|
32 780 000 000 |
|
Operating Income, £ |
|
|
4 357 000 000 |
6 433 000 000 |
6 745 000 000 |
4 021 000 000 |
8 338 000 000 |
|
8 415 000 000 |
|
EBITDA, £ |
? |
|
6 485 000 000 |
8 601 000 000 |
9 083 000 000 |
6 668 000 000 |
10 402 000 000 |
|
11 271 684 805 |
|
Net profit, £ |
? |
|
4 385 000 000 |
14 956 000 000 |
4 928 000 000 |
2 575 000 000 |
5 716 000 000 |
|
5 829 000 000 |
|
|
OCF, £ |
? |
|
7 952 000 000 |
8 160 543 693 |
7 890 893 093 |
6 554 000 000 |
7 142 957 939 |
|
8 300 913 532 |
|
CAPEX, £ |
? |
|
2 654 000 000 |
1 407 924 743 |
1 633 370 123 |
2 982 000 000 |
1 318 459 170 |
|
2 064 617 827 |
|
FCF, £ |
? |
|
5 298 000 000 |
6 752 618 950 |
6 257 522 970 |
3 572 000 000 |
5 824 498 768 |
|
6 236 295 705 |
|
Dividend payout, £
|
|
|
3 999 000 000 |
4 270 581 884 |
2 793 137 489 |
2 444 000 000 |
2 507 811 057 |
|
2 832 962 198 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
91.2% |
28.6% |
56.7% |
94.9% |
43.9% |
|
48.6% |
|
|
OPEX, £ |
|
|
12 176 000 000 |
13 337 000 000 |
15 018 000 000 |
18 307 000 000 |
15 312 000 000 |
|
15 410 000 000 |
|
Cost of production, £ |
|
|
8 163 000 000 |
9 554 000 000 |
8 565 000 000 |
9 048 000 000 |
9 017 000 000 |
|
8 955 000 000 |
|
R&D, £ |
|
|
5 019 000 000 |
5 488 000 000 |
6 223 000 000 |
6 401 000 000 |
7 525 000 000 |
|
7 755 000 000 |
|
Interest expenses, £ |
|
|
784 000 000 |
855 528 000 |
775 000 000 |
657 580 000 |
687 000 000 |
|
692 000 000 |
|
|
Assets, £ |
|
|
107 141 058 350 |
60 146 000 000 |
75 219 574 000 |
59 463 000 000 |
61 010 573 000 |
|
82 905 350 000 |
|
Net Assets, £ |
? |
|
20 391 244 750 |
10 598 000 000 |
17 014 755 600 |
13 671 000 000 |
16 348 214 000 |
|
23 541 432 000 |
|
Debt, £ |
|
|
32 741 119 850 |
20 987 000 000 |
22 969 346 400 |
16 986 000 000 |
17 688 854 000 |
|
25 129 147 000 |
|
Cash, £ |
|
|
5 871 540 750 |
7 877 000 000 |
6 606 013 600 |
3 714 000 000 |
3 400 013 000 |
|
4 540 284 000 |
|
Net debt, £ |
|
|
26 869 579 100 |
13 110 000 000 |
16 363 332 800 |
13 272 000 000 |
14 288 841 000 |
|
20 588 863 000 |
|
|
Ordinary share price, rub |
|
|
44.1 |
|
|
33.8 |
49.0 |
|
50.5 |
|
Number of ordinary shares, mln |
|
|
1 601 200 000 |
2 013 000 000 |
2 026 000 000 |
2 038 500 000 |
1 012 750 000 |
|
2 011 500 000 |
|
|
Market cap, £ |
|
|
70 612 920 000 |
0.00 |
0.00 |
68 942 070 000 |
49 665 260 000 |
|
101 661 210 000 |
|
EV, £ |
? |
|
97 482 499 100 |
13 110 000 000 |
16 363 332 800 |
82 214 070 000 |
63 954 101 000 |
|
122 250 073 000 |
|
Book value, £ |
|
|
-34 641 413 200 |
-10 766 000 000 |
-10 494 153 600 |
-8 826 000 000 |
-7 376 013 000 |
|
-9 986 516 000 |
|
|
EPS, rub |
? |
|
2.74 |
7.43 |
2.43 |
1.26 |
5.64 |
|
2.90 |
|
FCF/share, rub |
|
|
3.31 |
3.35 |
3.09 |
1.75 |
5.75 |
|
3.10 |
|
BV/share, rub |
|
|
-21.6 |
-5.35 |
-5.18 |
-4.33 |
-7.28 |
|
-4.96 |
|
|
EBITDA margin, % |
? |
|
26.3% |
29.3% |
29.9% |
21.3% |
31.8% |
|
34.4% |
|
Net margin, % |
? |
|
17.8% |
51.0% |
16.2% |
8.21% |
17.5% |
|
17.8% |
|
FCF yield, % |
? |
|
7.50% |
|
|
5.18% |
11.7% |
|
6.13% |
|
ROE, % |
? |
|
21.5% |
141.1% |
29.0% |
18.8% |
35.0% |
|
24.8% |
|
ROA, % |
? |
|
4.09% |
24.9% |
6.55% |
4.33% |
9.37% |
|
7.03% |
|
|
P/E |
? |
|
16.1 |
0.00 |
0.00 |
26.8 |
8.69 |
|
17.4 |
|
P/FCF |
|
|
13.3 |
0.00 |
0.00 |
19.3 |
8.53 |
|
16.3 |
|
P/S |
? |
|
2.86 |
0.00 |
0.00 |
2.20 |
1.52 |
|
3.10 |
|
P/BV |
? |
|
-2.04 |
0.00 |
0.00 |
-7.81 |
-6.73 |
|
-10.2 |
|
EV/EBITDA |
? |
|
15.0 |
1.52 |
1.80 |
12.3 |
6.15 |
|
10.8 |
|
Debt/EBITDA |
|
|
4.14 |
1.52 |
1.80 |
1.99 |
1.37 |
|
1.83 |
|
|
R&D/CAPEX, % |
|
|
189.1% |
389.8% |
381.0% |
214.7% |
570.7% |
|
375.6% |
|
|
CAPEX/Revenue, % |
|
|
10.7% |
4.80% |
5.39% |
9.50% |
4.04% |
|
6.30% |
|
| GlaxoSmithKline shareholders |
